NPS Executes On Ultra-Orphan Gattex Launch With FDA Approval In Hand
Executive Summary
NPS Pharmaceuticals will price the short bowel syndrome treatment at $295,000 per year – in line with the cost of other drugs in the ultra-orphan spectrum and higher than some industry observers expected – but said the addressable patient population is lower than it previously estimated.
You may also be interested in...
Deals Of The Week Looks At 2014 Takeout Targets
The hot field of immuno-oncology once again dominated the deal landscape with tie-ups between Bristol and Five Prime, Tesaro and AntaptysBio, and Medimmune and MD Anderson. Kythera and Bayer parted ways while Sanofi Pasteur teamed up with SK Chemicals.
NPS Hopes For A Happy New Year With Catalysts And Growth Ahead
The new year is set to be a pivotal one for the rare disease specialist, which expects to launch its short bowel disease drug teduglutide in Europe and have a second product, Natpara, approved in the U.S.
The Orphan Drug Boom: Gold Rush Or Flash In The Pan?
Rare disease drug development has ballooned in just three years, powered by the success of independent biotechs like Alexion, Big Pharma’s entrée into the field, and pressure from regulators and payors that is dis-incentivizing development of traditional primary care drugs. The positive momentum has intensified dealmaking in the orphan drug space and is giving investors confidence to back rare disease-focused start-ups. Some have coined the resulting movement the “orphan drug bubble,” but interest isn’t likely to deflate soon – at least not as long as Big Pharma continues to invest in the area and industry is able to sustain a favorable reimbursement climate for ultra-premium-priced drugs.